scispace - formally typeset
G

Giuseppe Del Giudice

Researcher at Novartis

Publications -  119
Citations -  6364

Giuseppe Del Giudice is an academic researcher from Novartis. The author has contributed to research in topics: Vaccination & Adjuvant. The author has an hindex of 39, co-authored 119 publications receiving 5728 citations.

Papers
More filters
Journal ArticleDOI

mTOR inhibition improves immune function in the elderly

TL;DR: MTOR inhibition by RAD001 improves immune responses in elderly volunteers receiving an influenza vaccination, raising the possibility that mTOR inhibition may have beneficial effects on immunosenescence in the elderly.
Journal ArticleDOI

Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST).

TL;DR: This study supports a possible protective role of vegetable intake in the intestinal type of GC and the ACO and finds a negative but non significant association between citrus fruit intake and the cardia site while no association was observed with the non‐cardia site.
Journal ArticleDOI

Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC).

TL;DR: Total, red, and processed meat intakes were associated with an increased risk of gastric non-cardia cancer, especially in H. pylori antibody-positive subjects, but not with cardia gastric cancer.
Journal ArticleDOI

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

TL;DR: Results support the use of adjuvants with flu vaccinations and could help expand coverage and decrease morbidity in the event of pandemic influenza and give vaccine makers the edge in a game of catch-up with dark horses.
Journal ArticleDOI

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.

TL;DR: While the unique anatomical predisposition of the facial nerve to compression suggests nasal delivery of neuronal-binding LT–derived adjuvants is inadvisable, their continued investigation as topical or mucosal adjuvant and antigens appears warranted on the basis of longstanding safety via oral, percutaneous, and other mucosal routes.